China Medical System Holdings Ltd. プレスリリース一覧

China Medical System (00867) Released its 2024 Interim Results: Steady Increase in Revenue and Profit Compared with 2H 2023
Aug 16, 2024 14:00 JST

On August 15, 2024, China Medical System Holdings Limited ("CMS" or the "Company") released its 2024 interim results announcement, with a steady increase in overall revenue and profit for the period compared to the second half (2H) of 2023. In the first half (1H) of 2024, the Company recorded a turnover of RMB3,611.1 million, representing a decrease of 21.7% compared with 1H 2023, an increase of 6.1% compared with 2H 2023.
More info..

China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China
Aug 05, 2024 23:00 JST

China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the "Product") has been approved by the National Medical Products Administration of China (NMPA).
More info..

China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating Jul 16, 2024 21:00 JST In July 2024, China Medical System Holdings Limited ("CMS" or the "Group") has once again been recognized for its outstanding performance and continuous progress in sustainable development. More info..

China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China
Jun 25, 2024 21:46 JST

On June 25, China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the "Product") in atopic dermatitis ("AD") in China.
More info..

China Medical System: Innovative Drug Methylthioninium Chloride Enteric-coated Sustained-release Tablets Approved for Marketing in China Jun 18, 2024 19:53 JST More info..

China Medical System: New Drug Application of Desidustat Tablets Accepted in China Apr 23, 2024 23:06 JST More info..

CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia Apr 01, 2024 21:30 JST More info..

China Medical System (867.HK) 2023 Annual Results: Despite of the Temporary Financial Performance Pressure, Fresh Catalysts Emerged from Successive Innovation Breakthroughs Mar 28, 2024 11:29 JST More info..

China Medical System (00867) Obtained Exclusive License of a First-line Phosphate-lowering Drug Velphoro(R) Feb 04, 2024 10:00 JST More info..

CMS(00867) Joins Hands with Pharmaron to Promote the Singapore Manufacturing Plant Acquisition and CDMO Business in SEA Jan 02, 2024 15:00 JST More info..

China Medical System: 4 Products Have Been Newly Included or Continued to be Included in the NRDL Dec 13, 2023 18:36 JST More info..

China Medical System Gained Exclusive License of an Anti-Ischemic Stroke Class 1 Innovative Drug Aug 24, 2023 21:00 JST More info..

China Medical System Once Again Received MSCI-ESG 'AA' Rating, Leading the Industry in ESG Management
Jul 31, 2023 21:00 JST

Recently, MSCI (Morgan Stanley Capital International), the world's largest index company, announced the latest Environmental, Social, and Governance (ESG) evaluation report for China Medical System Holdings limited ("CMS" or the "Group"), who achieved an "AA" rating and surpassed 75% of global peers with leading ESG management practices.
More info..

China Medical System: The first 'Diazepam Nasal Spray' Approved for Marketing in China Jun 12, 2023 21:00 JST More info..

China Medical System: An Innovative Drug, ILUMETRI 'Tildrakizumab Injection' Approved for Marketing in China
May 30, 2023 23:00 JST

On May 30, China Medical System Holdings Limited ("CMS" or the "Group") announced that on 26 May 2023, the New Drug Application (NDA) of Tildrakizumab Injection under the brand name of ILUMETRI has been approved by the National Medical Products Administration of China (NMPA). ILUMETRI is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
More info..